6533b7d3fe1ef96bd1260a24
RESEARCH PRODUCT
Treatments used for obsessive-compulsive disorder-An international perspective.
Kirupumani ViswasamLuana D. LauritoLuana D. LauritoYgor Arzeno FerrãoSriramya PotluriGiuseppe MainaBrian KayAmparo BellochBrenda E. BaileyChristine LochnerVladan StarcevicDonatella MarazzitiLeonardo F. FontenelleLeonardo F. FontenelleZhen WangLeto KalogerakiNaomi A. FinebergShyam Sundar ArumughamHisato MatsunagaMassimo PasquiniLena JelinekBrian C. RiemannVlasios BrakouliasIrakis MourikisTania BordaMartha J. FalkensteinRoseli Gendaki ShavittPedro MorgadoJanardhan Y. C. ReddyMaria Conceição Do RosárioJason A. EliasAndrew J. MartinLiliana Dell'ossoDan J. SteinEuripedes Constantino MiguelUmberto AlbertUmberto AlbertRodrigo Perez Riverasubject
MaleObsessive-Compulsive DisorderInternationalitymedicine.medical_treatmentDeep Brain StimulationSocial SciencesFluvoxamineBENZODIAZEPINASpharmacotherapyBenzodiazepines0302 clinical medicinePharmacology (medical)TERAPIA PSICOANALITICAPSICOFARMACOLOGIAantipsychotics; benzodiazepines; cross-cultural study; obsessive-compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsMiddle Aged3. Good healthExposure and response preventionantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitorsNeurologyPsychiatry and Mental HealthSerotonin Uptake Inhibitorscross-cultural studyAripiprazoleFemalebenzodiazepineSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychosurgeryAntipsychotic AgentsAdultmedicine.medical_specialty:Ciências da Saúde [Ciências Médicas]Ciências Médicas::Ciências da SaúdeSerotonin reuptake inhibitor03 medical and health sciencesANTIPSICOTICOSobsessive–compulsive disorderselective serotonin reuptake inhibitorsmedicinePSICOTROPICOSHumansAntipsychoticPsychiatryFARMACOTERAPIAFluoxetineRisperidoneantipsychotics; benzodiazepines; cross-cultural study; obsessive–compulsive disorder; pharmacotherapy; selective serotonin reuptake inhibitors; Neurology; Neurology (clinical); Psychiatry and Mental Health; Pharmacology (medical)Science & Technologyselective serotonin reuptake inhibitorbusiness.industryTRASTORNO OBSESIVO COMPULSIVO030227 psychiatryantipsychoticPsychosurgeryantipsychoticsNeurology (clinical)business030217 neurology & neurosurgerySEROTONINAdescription
Objective The objective of this study was to characterise international trends in the use of psychotropic medication, psychological therapies, and novel therapies used to treat obsessive–compulsive disorder (OCD). Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their samples. Consistency of summary statistics across countries was evaluated. Results The study surveyed 19 expert centres from 15 countries (Argentina, Australia, Brazil, China, Germany, Greece, India, Italy, Japan, Mexico, Portugal, South Africa, Spain, the United Kingdom, and the United States) providing a total sample of 7,340 participants. Fluoxetine (n = 972; 13.2%) and fluvoxamine (n = 913; 12.4%) were the most commonly used selective serotonin reuptake inhibitor medications. Risperidone (n = 428; 7.3%) and aripiprazole (n = 415; 7.1%) were the most commonly used antipsychotic agents. Neurostimulation techniques such as transcranial magnetic stimulation, deep brain stimulation, gamma knife surgery, and psychosurgery were used in less than 1% of the sample. There was significant variation in the use and accessibility of exposure and response prevention for OCD. Conclusions The variation between countries in treatments used for OCD needs further evaluation. Exposure and response prevention is not used as frequently as guidelines suggest and appears difficult to access in most countries. Updated treatment guidelines are recommended.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-09-11 | Human psychopharmacology |